NCT06106594
VOLT CE Mark Study
StatusActive, Not Recruiting
PhaseNot applicable
SponsorAbbott Medical Devices
Primary completion (estimated)
At risk: Primary completion moved at least 6 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 5 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jun 2026 to Jan 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 24 words
- Primary endpoints: details revised at 2 of 3 entries
- Study completion date: Dec 2026 to Jan 2027
- Publications: details revised at 2 of 2 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 16 to 11
Notable Trial status: Active, Not Recruiting to Recruitingv6 Show 6 more changesShow less
- Primary completion date: Sep 30, 2024 to Jun 2026
- Enrollment target: 250 to 300
- Study sites: 11 to 16
- Study completion date: Sep 2026 to Dec 2026
- Study description revised
- Publications: details revised at 2 of 2 entries
Notable Lead sponsor: [Redacted] to Abbott Medical Devicesv5 Show 5 more changesShow less
- Trial status: Withheld to Active, Not Recruiting
- Primary completion date: Sep 30, 2024
- Study completion date: Sep 2026
- Start date: Oct 24, 2023
- Study title shortened, about 9 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Rate of subjects experiencing a device and/or procedure-related serious adverse event with onset within 7-days of any ablation procedure that uses the Volt PFA System.
Timeframe: 7-days
Acute procedural effectiveness summarized as the rate of pulmonary veins treated with the Volt PFA system that are isolated at the end of the index ablation procedure.
Timeframe: During procedure
Long-term 6-month effectiveness summarized as the rate of freedom from documented AF/AFL/AT episodes of >30 seconds duration after the index ablation procedure through 6 months of follow-up.
Timeframe: 6 months
Arms and interventions
Volt PFA Catheter Sensor Enabled (SE)Experimental
Devices: Pulsed Field Ablation
Sites
11 sites in 7 countries
Australia 4, Belgium 2, Austria 1, Czechia 1, Germany 1, Netherlands 1, Spain 1